Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Wednesday preview: GSK results among the highlights
(Sharecast News) - Wednesday sees the release of full-year and fourth-quarter results from drugs giant GSK, while DCC, SSE and Watches of Switzerland will publish third-quarter trading statements. As far as DCC is concerned, UBS said the company is becoming a pure-play energy business so the performance of this division will be a key focus for investors.
"And as ever with DCC, the market will be looking for any M&A announcements or updates on their plans to sell the remaining technology business," the bank said.
"DCC typically does not provide quantitative guidance for the next financial year, but management are currently guiding for 'good' operating profit growth for FY'26e overall."
In Europe, results are due from Novo Nordisk, Banco Santander, UBS and Carlsberg, among others.
Derren Nathan, head of equity analysis at Hargreaves Lansdown, said investor sentiment towards Novo Nordisk bottomed out following another downgrade to revenue and profit guidance at its third-quarter update in November.
"Ignoring exchange rate moves, 2025 full-year revenue is now expected to rise 8-11%, with operating profit growth faring worse at 4-7%," he said. "But it's been a promising start to 2026, with take-up of the company's recently launched Wegovy pill for weight management helping to claw back some US market share from arch-rival, Eli Lilly.
"Attention now turns to this year's outlook, with pricing and insurance coverage likely to be key points of focus. It's a complex picture, but, on balance, we think there could be some upside to consensus forecasts of a small fall in 2026 sales. Of course there can be no guarantee, but recent strength in the valuation suggests we're unlikely to be alone in this view."
Across the pond, Alphabet, Uber Technologies, Qualcomm and Boston Scientific are slated to report, along with CostCo.
Wednesday February 04
QUARTERLY PAYMENT DATE
British American Tobacco
INTERNATIONAL ECONOMIC ANNOUNCEMENTS
Crude Oil Inventories (US) (15:30)
Factory Orders (US) (15:00)
ISM Prices Paid (US) (15:00)
ISM Services (US) (15:00)
MBA Mortgage Applications (US) (12:00)
PMI Composite (EU) (09:00)
PMI Composite (GER) (08:55)
PMI Composite (US) (14:45)
PMI Services (EU) (09:00)
PMI Services (GER) (08:55)
PMI Services (US) (14:45)
Producer Price Index (EU) (10:00)
Q4
GSK
FINALS
GSK
EGMS
IG Design Group
AGMS
AJ Bell, Premier Miton Group, Watkin Jones
TRADING ANNOUNCEMENTS
DCC (CDI), Entain, Gem Diamonds Ltd. (DI), Watches of Switzerland Group
UK ECONOMIC ANNOUNCEMENTS
PMI Composite (09:30)
PMI Services (09:30)
FINAL DIVIDEND PAYMENT DATE
AJ Bell
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
